Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

NCT01296763 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Irinotecan
DRUG: Cisplatin
DRUG: Olaparib (for levels 1 and 5)
DRUG: Olaparib (for dose level 2)
DRUG: Mitomycin-C

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]